Policy & Regulation
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
14 July 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) on Tuesday announced an agreement to sell ridinilazole, an investigational Phase III precision antibiotic, to To...
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
14 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the European Commission has approved an updated label for Erbi...
Servier acquires Edgewise Therapeutics' muscular dystrophy business
14 July 2026 - French pharmaceutical company Servier announced on Monday that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc (Nasdaq:EWTX) following r...
Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker
13 July 2026 - Japanese pharmaceutical company Eisai Co., Ltd. (TYO: 4523) on Monday reported new findings showing that its investigational anti-MTBR antibody etalanetug (E2814) reduced levels of plas...
Takeda and Indonesia launch partnership to expand plasma-derived medicine production
13 July 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) announced on Monday that it has entered into a multi-year collaboration with the Indonesian government to strengthen the cou...